Intended for healthcare professionals


Pre-eclampsia: FDA approves blood test to identify pregnant women at risk

BMJ 2023; 382 doi: (Published 11 July 2023) Cite this as: BMJ 2023;382:p1594
  1. Janice Hopkins Tanne
  1. New York

A blood test that predicts the risk of pre-eclampsia, intended as an early warning in pregnant women who are already in hospital with hypertensive disorder of pregnancy, has been approved by the US Food and Drug Administration (FDA). The test is already used in Europe.

The test, marketed by Thermo Fisher Scientific, is an immunoassay that measures the ratio of serum soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) in women who are admitted to hospital for hypertensive disorders of pregnancy. The test is the first of its kind, and it predicted with 96% accuracy the women who would not develop severe pre-eclampsia within the next …

View Full Text

Log in

Log in through your institution


* For online subscription